{
    "name": "rasburicase",
    "comment": "Rx",
    "other_names": [
        "Elitek"
    ],
    "classes": [
        "Enzymes",
        "Oncology"
    ],
    "source": "https://reference.medscape.com/drug/elitek-rasburicase-342255",
    "pregnancy": {
        "common": [
            "The limited available data in pregnant women are insufficient to inform a drug- associated risk of major birth defects, miscarriage, or adverse maternal fetal outcomes; consider benefits and risks of therapy and possible risks to fetus when prescribing therapy to a pregnant woman"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "Based on findings in animals, drug may cause fetal harm when administered to pregnant women; in animal reproduction studies, intravenous administration to pregnant rabbits during organogenesis at 5-times human exposure (based on AUC) at recommended human dose of 0.2 mg/kg resulted in adverse developmental outcomes, including structural abnormalities, embryo-fetal mortality, and alterations to growth"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There are no available data on presence of drug in human breast milk, effects on breastfed child, or on milk production; because of potential for serious adverse reactions in breastfed child, advise patients that breastfeeding is not recommended during treatment, and for 2 weeks after last dose"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [
                "May cause serious hypersensitivity reactions, including anaphylaxis. Should be immediately and permanently discontinued in any patient developing clinical evidence of a serious hypersensitivity reaction.",
                "When administered to patients with G-6-PD deficiency, this agent can cause severe hemolysis.",
                "Should be immediately and permanently discontinued in any patient developing hemolysis. It is recommended that patients at a higher risk for G-6-PD deficiency (eg, patients of African or Mediterranean ancestry) be screened prior to starting rasburicase.",
                "Rasburicase use has been associated with methemoglobinemia. Should be immediately and permanently discontinued in any patient developing methemoglobinemia.",
                "Rasburicase causes enzymatic degradation of the uric acid within blood samples left at room temperature, resulting in spuriously low uric acid levels. To ensure accurate measurements, blood must be collected into prechilled tubes containing heparin anticoagulant and immediately immersed and maintained in an ice water bath; plasma samples must be assayed within 4 hours of sample collection."
            ],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity",
                "G6PD deficiency",
                "History of hemolysis or methemoglobinemia reactions to rasburicase"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Hypersensitivity reactions can occur at any time during treatment including first dose; signs and symptoms of these reactions include bronchospasm, chest pain and tightness, dyspnea, hypoxia, hypotension, shock, and urticaria; immediately and permanently discontinue administration in any patient developing clinical evidence of a serious hypersensitivity reaction; safety and efficacy have been established only for a single course of treatment once daily for 5 days",
                "Screen patients for G6PD deficiency (eg, patients of African or Mediterranean ancestry); contraindicated in patients with G6PD deficiency because hydrogen peroxide is one of the major by-products of the conversion of uric acid to allantoin; severe hemolytic reactions may occur within 2-4 days of the start of therapy; immediately and permanently discontinue therapy in any patient developing hemolysis; institute appropriate patient monitoring and support measures (eg, transfusion support)",
                "Patients should receive adequate hydration as part of uric acid management",
                "Efficacy may be reduced with subsequent courses of therapy due to its immunogenic characteristics; can elicit an antibody response",
                "Methemoglobinemia has included cases of serious hypoxemia requiring intervention with medical support measures; not known whether patients with deficiency of cytochrome b5 reductase (formerly known as methemoglobin reductase) or of other enzymes with antioxidant activity are at increased risk for methemoglobinemia or hemolytic anemia; immediately and permanently discontinue therapy in any patient identified as having developed methemoglobinemia; institute appropriate monitoring and support measures (eg, transfusion support, methylene-blue administration)",
                "Interferes with serum uric acid measurement unless blood sample chilled immediately and assayed within 4 hr"
            ],
            "specific": []
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Vomiting",
            "percent": "50"
        },
        {
            "name": "Fever",
            "percent": "46"
        },
        {
            "name": "Nausea",
            "percent": "27"
        },
        {
            "name": "Headache",
            "percent": "26"
        },
        {
            "name": "Abdominal pain",
            "percent": "20"
        },
        {
            "name": "Constipation",
            "percent": "20"
        },
        {
            "name": "Diarrhea",
            "percent": "20"
        },
        {
            "name": "Mucositis",
            "percent": "15"
        },
        {
            "name": "Rash",
            "percent": "13"
        },
        {
            "name": "Neutropenia",
            "percent": "2-4"
        },
        {
            "name": "Respiratory distress",
            "percent": "3"
        },
        {
            "name": "Hyperphosphatemia",
            "percent": "10"
        },
        {
            "name": "Sepsis",
            "percent": "3"
        },
        {
            "name": "Neutropenic fever",
            "percent": "4"
        },
        {
            "name": "Anaphylaxis",
            "percent": null
        },
        {
            "name": "Hemolysis",
            "percent": null
        },
        {
            "name": "Methemoglobinemia",
            "percent": null
        },
        {
            "name": "Severe rash",
            "percent": null
        },
        {
            "name": "Dehydration",
            "percent": null
        },
        {
            "name": "Acute renal failure",
            "percent": null
        },
        {
            "name": "Pancytopenia",
            "percent": null
        },
        {
            "name": "Myocardial infarction",
            "percent": null
        },
        {
            "name": "Cellulitis",
            "percent": null
        },
        {
            "name": "Cardiac failure",
            "percent": null
        },
        {
            "name": "Hot flashes",
            "percent": null
        },
        {
            "name": "Central nervous system disorders",
            "percent": null
        },
        {
            "name": "Convulsion",
            "percent": null
        },
        {
            "name": "muscle contractions involuntary",
            "percent": null
        },
        {
            "name": "Anaphylaxis",
            "percent": null
        }
    ]
}